Overview

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter, exploratory, single arm, two-stage study aiming to explore efficacy and safety of lenalidomide and dexamethasone combination (LD) as first line therapy in previously untreated patients with primary Plasma Cell leukemia (PPCL).
Phase:
Phase 2
Details
Lead Sponsor:
IRCCS Centro di Riferimento Oncologico della Basilicata
Collaborator:
Celgene Corporation
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide